EQS-News: Formycon AG / Key word(s): Scientific publication/Study results Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed ...

Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel 13.01.2025 / 07:00 CET/CEST The issuer is ...

Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis ® 2 (ranibizumab) in Europe The partnership broadens Teva's ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ...

Formycon AG (XTER:FYB) achieved two FDA approvals and two positive CHMP opinions for its biosimilars, FYB202 and FYB203, in a shorter time than the industry average. The company successfully ...

Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda ® in peer-reviewed journal Drugs in R&D The comparative analytical evaluation results indicate ...

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1 Agreement builds on the proven and successful ...